Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

844.02 +3.52 (+0.42%)
Streaming Delayed Price Updated: 1:21 PM EST, Feb 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about argenx SE - American Depositary Shares

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
News headline image
argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American Academy of Neurology Annual Meeting
From argenx SE
Via Business Wire
News headline image
The Daily Biotech Pulse: Pfizer Reports Positive Ulcerative Colitis Study Data, Novavax COVID Shot Authorized For Adolescents In India, Argenx Stock Sale ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
Piper Comments On Increased Interest To Invest In Arcturus, 'Incrementally Positive' On Argenx ↗
Piper Sandler noted that Arcturus Therapeutics Holdings Inc's (NASDAQ: ARCT) recently filed 10-K mentions funding of $25 million from a "pharmaceutical... 
Via Benzinga
News headline image
Argenx's Subcutaneous Efgartigimod At Par With Intravenous Administration In Neuromuscular Disorder ↗
Argenx SE (NASDAQ: ARGX) ) has  
Via Benzinga
News headline image
Recap: argenx Q4 Earnings ↗
argenx (NASDAQ:ARGX) reported its Q4 earnings results on Thursday, March 3, 2022 at 01:00 AM. Here's what investors need to know about the announcement. Earnings argenx... 
Via Benzinga
News headline image
argenx's Earnings: A Preview ↗
argenx (NASDAQ:ARGX) is set to give its latest quarterly earnings report on Thursday, 2022-03-03. Here's what investors need to know before the announcement. Analysts estimate... 
Via Benzinga
News headline image
What 8 Analyst Ratings Have To Say About argenx ↗
Analysts have provided the following ratings for argenx (NASDAQ:ARGX) withi... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Pfizer Strikes COVID-19 Pill Supply Deal, Argenx Reports Positive Late-Stage Readout ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
argenx Announces Positive Topline Phase 3 Data From ADAPT-SC Study Evaluating Subcutaneous Efgartigimod for Generalized Myasthenia Gravis
From argenx SE
Via Business Wire
News headline image
What 8 Analyst Ratings Have To Say About argenx ↗
argenx (NASDAQ:ARGX) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 3 4... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Novavax COVID Shot Authorized In Australia, Zymeworks Restructures, Orphan Drug Designation For Marker's Pancreatic Cancer Drug ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Eisai Announces Publication Of Positive Data On Lenvima-Keytruda Combo In... 
Via Benzinga
News headline image
What 8 Analyst Ratings Have To Say About argenx ↗
Within the last quarter, argenx (NASDAQ:ARGX) has observed the following an... 
Via Benzinga
News headline image
Analyst Ratings For argenx ↗
Analysts have provided the following ratings for argenx (NASDAQ:ARGX) withi... 
Via Benzinga
News headline image
Earnings Scheduled For March 3, 2022 ↗
Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban... 
Via Benzinga
News headline image
argenx Announces VYVGART™ Approval in Japan for the Treatment of Generalized Myasthenia Gravis
From argenx
Via Business Wire
News headline image
argenx Highlights Strategic Priorities for 2022
From argenx
Via Business Wire
News headline image
38 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Society Pass Incorporated (NASDAQ: SOPA) shares jumped 120.9% to $7.31 after the company reported addition to the Russell 2000 Index. Can-Fite BioPharma Ltd. (NYSE: CANF... 
Via Benzinga
News headline image
65 Biggest Movers From Yesterday ↗
Gainers Society Pass Incorporated (NASDAQ: SOPA) shares climbed 240.2% to close at $11.26 on Monday after the company reported addition to the Russell 2000 Index. Bluerock... 
Via Benzinga
News headline image
Argenx's Vyvgart Wins FDA Approval For Autoimmune, Neuromuscular Disease ↗
The FDA has approved Argenx SE's (NASDAQ: ARGX) Vyvgart (efgartigimod alfa-fcab) for generalized myasthenia gravis (gMG) in adult patients who are anti-... 
Via Benzinga
News headline image
A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street; Crude Oil Down 4% ↗
Pre-open movers U.S. stock futures traded lower in early pre-market trade after the Dow Jones tumbled more than 500 points in the previous session. The Federal Reserve, last week... 
Via Benzinga
News headline image
5 Stocks To Watch For December 20, 2021 ↗
Some of the stocks that may grab investor focus today are: Wall Street expects Carnival Corporation (NYSE: CCL) to report a quarterly loss at $1.27 per share on revenue of $1.... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Dec. 19-25): Key Events Of Holiday-Shortened Week ↗
Biotech stocks reversed course and advanced solidly in the week ending Dec. 17, as an increase in risk aversion pushed investors to buy into defensive stocks. The sector also drew strength from some... 
Via Talk Markets
News headline image
The Week Ahead In Biotech (Dec. 19-25): Amgen And Aquestive Regulatory Decisions Key Events Of Holiday-Shortened Week ↗
Biotech stocks reversed course and advanced solidly in the week ending Dec. 17, as an increase in risk aversion pushed investors to buy into defensive stocks. The sector also... 
Via Benzinga
News headline image
argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis
From argenx SE
Via Business Wire
News headline image
The Daily Biotech Pulse: Genfit Spikes On Liver Disease Drug Licensing Deal, Lyell Gets Nod For Solid Tumor Study, Decision-Day For Intra-Cellular, Argenx ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Merck Announces Publication Of Positive Data From Late-Stage Study Of Oral... 
Via Benzinga
News headline image
2 Mid-Cap Biopharma Stocks BofA Securities Recommends For 2022 ↗
Biotech stocks are risky investments and to make a profit informed decision-making is needed. BofA Securities announced its ... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Dec. 12-18): Hematology Conference Presentations, FDA Decisions For Calliditas, Argenx, Intra-Cellular & Eagle Pharma And More ↗
Biotech stocks closed out the week ending Dec. 10 with modest losses as investors moved money out of defensives and into risky bets amid the broader market rebound. Multiple... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For December 8, 2021 ↗
Upgrades According to Deutsche Bank, the prior rating for Goodyear Tire & Rubber Co (NASD... 
Via Benzinga
News headline image
Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates ↗
A majority of verdicts handed down by the FDA in November were positive. Three new molecular entities were approved during the month, taking the total number of NME approvals for... 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About argenx ↗
Over the past 3 months, 4 analysts have published their opinion on argenx (NASDAQ: 
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.